Profile data is unavailable for this security.
About the company
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.
- Revenue in USD (TTM)5.18m
- Net income in USD-7.79m
- Incorporated2007
- Employees4.00
- LocationEvoke Pharma Inc420 Stevens Avenue, Suite 370SOLANA BEACH 92075United StatesUSA
- Phone+1 (858) 345-1494
- Fax+1 (302) 636-5454
- Websitehttps://evokepharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Resonate Blends Inc | 16.47k | -1.42m | 3.75m | 6.00 | -- | -- | -- | 227.75 | -0.0178 | -0.0178 | 0.0002 | -0.0247 | 0.0237 | -- | -- | -- | -203.52 | -680.29 | -- | -- | -593.02 | -78.88 | -8,597.33 | -12,895.26 | -- | -0.4691 | 7.89 | -- | -66.73 | -56.57 | -316.63 | -- | -- | -- |
Atreca Inc | 0.00 | -97.76m | 3.77m | 90.00 | -- | 0.3499 | -- | -- | -2.49 | -2.49 | 0.00 | 0.2715 | 0.00 | -- | -- | 0.00 | -98.54 | -44.99 | -116.19 | -48.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 11.13 | -- | -8.46 | -- |
Bon Natural Life Ltd | 29.52m | 4.60m | 3.83m | 96.00 | 0.5511 | 0.091 | 0.696 | 0.1298 | 4.99 | 4.99 | 32.10 | 30.23 | 0.7045 | 15.27 | 5.19 | 307,524.60 | 10.86 | 14.04 | 13.69 | 20.68 | 29.94 | 30.00 | 15.42 | 17.62 | 2.41 | 30.54 | 0.0955 | 0.00 | -1.29 | 22.32 | -26.32 | 83.09 | -6.70 | -- |
Geovax Labs Inc | 0.00 | -25.97m | 3.92m | 17.00 | -- | 0.5832 | -- | -- | -14.25 | -14.25 | 0.00 | 2.91 | 0.00 | -- | -- | 0.00 | -127.82 | -108.34 | -160.47 | -147.24 | -- | -- | -- | -1,842.93 | -- | -- | 0.00 | -- | -100.00 | -- | -85.20 | -- | -- | -- |
Evoke Pharma Inc | 5.18m | -7.79m | 3.98m | 4.00 | -- | -- | -- | 0.7691 | -2.33 | -2.33 | 1.55 | -0.7716 | 0.5476 | 0.5235 | 7.98 | 1,295,158.00 | -82.37 | -100.48 | -109.52 | -151.10 | 96.10 | -- | -150.41 | -480.52 | 2.09 | -20.56 | 2.07 | -- | 106.51 | -- | 5.25 | -- | -- | -- |
Zyversa Therapeutics Inc | 0.00 | -106.25m | 4.02m | 7.00 | -- | 0.1936 | -- | -- | -1,922.89 | -1,922.89 | 0.00 | 27.33 | 0.00 | -- | -- | 0.00 | -139.81 | -- | -160.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -340.15 | -- | -- | -- |
Seelos Therapeutics Inc | 2.20m | -37.88m | 4.03m | 15.00 | -- | -- | -- | 1.83 | -8.95 | -8.95 | 0.4402 | -3.42 | 0.1564 | -- | -- | 146,866.70 | -269.01 | -180.05 | -- | -386.76 | -- | -- | -1,719.56 | -9,612.88 | -- | -- | -- | -- | -- | -- | 48.48 | -- | -- | -- |
Bio Path Holdings Inc | 0.00 | -16.08m | 4.04m | 10.00 | -- | 3.62 | -- | -- | -35.76 | -35.76 | 0.00 | 0.7136 | 0.00 | -- | -- | 0.00 | -167.56 | -70.80 | -206.12 | -76.87 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.94 | -- | -- | -- |
Petros Pharmaceuticals Inc | 5.82m | -13.81m | 4.04m | 21.00 | -- | 0.1457 | -- | 0.6944 | -6.35 | -6.35 | 2.74 | 4.17 | 0.1759 | 0.9524 | 2.69 | 277,256.70 | -24.66 | -32.43 | -33.75 | -68.05 | 71.98 | 62.04 | -140.20 | -201.70 | 1.74 | -- | 0.391 | -- | -2.83 | -16.15 | 31.06 | -- | -- | -- |
Clearmind Medicine Inc | 0.00 | -8.09m | 4.09m | -- | -- | 0.811 | -- | -- | -30.92 | -30.92 | 0.00 | 1.59 | 0.00 | -- | -- | -- | -109.55 | -218.20 | -180.61 | -488.96 | -- | -- | -- | -- | -- | -2.90 | 0.0184 | -- | -- | -- | -25.03 | -- | -- | -- |
Sentient Brands Holdings Inc | 160.00 | -379.70k | 4.12m | 2.00 | -- | -- | -- | 25,748.21 | -0.007 | -0.007 | 0.00 | -0.0308 | 0.0006 | -0.0026 | -- | 80.00 | -149.74 | -224.47 | -- | -- | 462.50 | 41.35 | -237,312.50 | -27,393.23 | 0.0005 | -0.6995 | -- | -- | -16.18 | -- | -100.19 | -- | -- | -- |
Alzamend Neuro Inc | 0.00 | -15.16m | 4.13m | 4.00 | -- | -- | -- | -- | -2.32 | -2.32 | 0.00 | -0.4146 | 0.00 | -- | -- | 0.00 | -265.85 | -- | -496.81 | -- | -- | -- | -- | -- | -- | -1,736.10 | -- | -- | -- | -- | -20.35 | -- | -- | -- |
Cyclacel Pharmaceuticals Inc | 420.00k | -22.76m | 4.16m | 12.00 | -- | 4.95 | -- | 9.89 | -26.72 | -26.72 | 0.4924 | 0.5732 | 0.0228 | -- | 0.1106 | -- | -122.40 | -57.58 | -212.95 | -69.81 | -- | -- | -5,370.24 | -18,789.29 | -- | -170.83 | 0.00 | -- | -- | 22.87 | -6.34 | -- | -31.23 | -- |
Twinlab Consolidated Holdings Inc | 13.62m | -9.66m | 4.21m | 17.00 | -- | -- | -- | 0.3092 | -0.0373 | -0.0529 | 0.0526 | -0.5366 | 0.9106 | 1.34 | 4.41 | 801,000.00 | -64.61 | -60.53 | -- | -- | 36.81 | 21.36 | -70.96 | -37.72 | 0.0157 | -0.0516 | -- | -- | -20.87 | -28.58 | -20.28 | -- | -- | -- |
Ensysce Biosciences Inc | 2.23m | -10.63m | 4.21m | 7.00 | -- | -- | -- | 1.89 | -5.28 | -5.28 | 0.9876 | -0.1026 | 0.5191 | -- | 11.92 | 318,645.70 | -247.32 | -17.68 | -- | -19.42 | -- | -- | -476.40 | -715.78 | -- | -30.28 | 4.20 | -- | -11.61 | -- | 57.64 | -- | -- | -- |
Exicure Inc | 23.79m | 3.07m | 4.24m | 7.00 | 0.3833 | 0.4367 | 1.03 | 0.1781 | 1.28 | 1.28 | 3.86 | 1.12 | 0.8729 | -- | -- | 1,830,000.00 | 11.25 | -41.75 | 18.34 | -55.57 | -- | -- | 12.88 | -302.07 | -- | -- | 0.00 | -- | 6,068.12 | 24.29 | 95.97 | -- | -59.57 | -- |
Holder | Shares | % Held |
---|---|---|
AIGH Capital Management LLCas of 09 Feb 2024 | 825.00k | 9.73% |
Altium Capital Management LPas of 09 Feb 2024 | 822.99k | 9.71% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 29.85k | 0.35% |
Geode Capital Management LLCas of 31 Dec 2023 | 27.07k | 0.32% |
Tower Research Capital LLCas of 31 Dec 2023 | 6.45k | 0.08% |
UBS Securities LLCas of 31 Dec 2023 | 1.81k | 0.02% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 1.46k | 0.02% |
UBS Financial Services, Inc.as of 31 Dec 2023 | 1.11k | 0.01% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2023 | 375.00 | 0.00% |
NewEdge Advisors LLCas of 31 Dec 2023 | 208.00 | 0.00% |